
Alpha Profiles · Company Profile
Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
https://registry.alpha.ac/companies/tenaya-therapeutics-inc
- Entity
- Public listing published
- Primary listing
- NASDAQ: TNYA
- Verification
- Partially verified
- Last reviewed
- 2026-09-16T04:46:37.602669+00:00
Overview
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacet
Source record
Alpha canonical company public projection
Supports Company identity, Published leadership, Entity status boundary
Reviewed 2026-09-16T04:46:37.602669+00:00
